Skip to main content
. 2014 Apr 24;19(4):5402–5420. doi: 10.3390/molecules19045402

Table 5.

In vitro susceptibility of clinical isolates of Cryptococcus neoformans for pentakis-dithiocarbamate diruthenium complexes by broth microdilution methods—MIC: μg mL−1 (10−5 mol L−1).

Compounds Cryptococcus neoformans Compounds Cryptococcus neoformans
L1 16.0 (11.2) L6 16.0 (9.45)
C1 16.0 (1.99) C6 16.0 (1.71)
L2 16.0 (9.34) L7 16.0 (8.73)
C2 16.0 (1.70) C7 16.0 (1.59)
L3 16.0 (9.34) L8 64.0 (34.5)
C3 64.0 (6.80) C8 32.0 (3.16)
L4 16.0 (10.2) L9 128 (47.9)
C4 32.0 (3.66) C9 16.0 (1.02)
L5 32.0 (16.0) RuCl3 >512 (196)
C5 16.0 (1.48) FLU 2.0 (0.65)